Standout Papers

Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and e... 2020 2026 2022 2024300
  1. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial (2020)
    Nirav N. Shah, Bryon D. Johnson et al. Nature Medicine

Immediate Impact

19 by Nobel laureates 41 from Science/Nature 63 standout
Sub-graph 1 of 23

Citing Papers

Natural killer cell therapies
2024 StandoutNature
CAR-T cell manufacturing: Major process parameters and next-generation strategies
2024 Standout
2 intermediate papers

Works of Michael J. Kadan being referenced

Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial
2020 Standout

Author Peers

Author Last Decade Papers Cites
Michael J. Kadan 428 350 393 16 805
Amilia Meir 272 188 480 12 733
Nike Beaubier 316 225 467 16 940
Pranay D. Khare 188 185 397 16 683
Michael A. Perricone 418 261 119 22 891
Huaigeng Xu 727 154 285 12 947
Ulrike Mock 514 264 450 20 825
Paul Clark 575 146 261 24 978
Eric Chen 176 212 542 12 801
Elie G. Hanania 400 186 183 24 788
Ming-Ru Wu 342 121 415 18 816

All Works

Loading papers...

Rankless by CCL
2026